Successes using magnetic fields to deliver modified nanoparticles to the tumor sites are described, with the benefit of decreasing necessary chemotherapeutic doses.15,16 Studies detailing the modification and engineering of magnetic nanoparticles for targeted drug delivery exist.12–14 Using these well-described techniques, the authors of the current report have modified magnetic nanoparticles by way of conjugation to vascular endothelial growth factor (VEGF) antibody and ligand cluster of differentiation 80 (CD80).13 The gene discussed is CD80; the disease is neoplasm.